MedTrace Logo

Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC

NCT05494697 · Status: SUSPENDED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2025-10-14

No results posted yet for this study

Summary

The purpose of this study is to assess the safety and efficacy of Ampligen in patients with locally advanced pancreatic adenocarcinoma

Conditions

Interventions

DRUG

Rintatolimod

Rintatolimod (poly I : poly C12U)

Sponsors & Collaborators

Principal Investigators

  • David R Strayer, MD · AIM ImmunoTech Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-30
Primary Completion
2029-12-31
Completion
2030-01-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05494697 on ClinicalTrials.gov